Vascular Biogenics Valuation
| VBLTDelisted Stock | USD 0.28 0.01 3.45% |
Vascular Biogenics seems to be overvalued based on Macroaxis valuation methodology. Our model measures the value of Vascular Biogenics from inspecting the company fundamentals such as Return On Equity of -0.6, shares owned by insiders of 13.48 %, and Current Valuation of (10.99 M) as well as reviewing its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Vascular Biogenics' price fluctuation is very steady at this time. Calculation of the real value of Vascular Biogenics is based on 3 months time horizon. Increasing Vascular Biogenics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Vascular Biogenics' intrinsic value may or may not be the same as its current market price of 0.28, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.28 | Real 0.22 | Hype 0.28 | Naive 0.27 |
The intrinsic value of Vascular Biogenics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Vascular Biogenics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Vascular Biogenics helps investors to forecast how Vascular stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Vascular Biogenics more accurately as focusing exclusively on Vascular Biogenics' fundamentals will not take into account other important factors: Vascular Biogenics Total Value Analysis
Vascular Biogenics is at this time expected to have valuation of (10.99 M) with market capitalization of 13.83 M, debt of 564 K, and cash on hands of 34.15 M. The negative valuation of Vascular Biogenics may imply that the market is not capable to price the future growth of the company or it is pricing it at zero value. It may also suggest that takeover valuation may not have captured all of the outstanding financial obligations of the company both on and off balance sheet. Investors should vigilantly validate all of the Vascular Biogenics fundamentals.| Takeover Price | Market Cap | Debt Obligations | Cash |
(10.99 M) | 13.83 M | 564 K | 34.15 M |
Vascular Biogenics Investor Information
About 13.0% of the company outstanding shares are owned by insiders. The company has Price to Book (P/B) ratio of 0.35. Historically many companies with similar price-to-book (P/B) ratio do better than the market in the long run. Vascular Biogenics recorded a loss per share of 0.18. The entity had not issued any dividends in recent years. Based on the key indicators related to Vascular Biogenics' liquidity, profitability, solvency, and operating efficiency, Vascular Biogenics is not in a good financial situation at the moment. It has a very high risk of going through financial straits in January.Vascular Biogenics Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Vascular Biogenics has an asset utilization ratio of 2.22 percent. This implies that the Company is making $0.0222 for each dollar of assets. An increasing asset utilization means that Vascular Biogenics is more efficient with each dollar of assets it utilizes for everyday operations.Vascular Biogenics Ownership Allocation
Vascular Biogenics shows a total of 77.64 Million outstanding shares. Vascular Biogenics has 13.48 % of its outstanding shares held by insiders and 14.0 % owned by institutional holders. Please note that no matter how many assets the company owns, if the real value of the company is less than the current market value, you may not be able to make money on it.Vascular Biogenics Profitability Analysis
The company reported the previous year's revenue of 658 K. Net Loss for the year was (32.3 M) with profit before overhead, payroll, taxes, and interest of 554 K.About Vascular Biogenics Valuation
The delisted stock valuation mechanism determines Vascular Biogenics' current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of Vascular Biogenics based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of Vascular Biogenics. We calculate exposure to Vascular Biogenics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Vascular Biogenics's related companies.Vascular Biogenics Ltd., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of cancer and immune-inflammatory diseases in Israel and the United States. Vascular Biogenics Ltd. was incorporated in 2000 and is headquartered in Modiin, Israel. Vascular Biogen operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 41 people.
Vascular Biogenics Growth Indicators
Investing in growth stocks can be very risky. If the company such as Vascular Biogenics does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 77.6 M |
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Stock Screener module to find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook..
Other Consideration for investing in Vascular Stock
If you are still planning to invest in Vascular Biogenics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Vascular Biogenics' history and understand the potential risks before investing.
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. |